Erratum: Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile (Kidney International (2010) 78:118 (S15-S21) DOI:10.1038/ki.2010.211);Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile

Kidney International

Volumn 78, Issue SUPPL. 118, 2010, Pages 1192-

  Djamali, Arjang ^a   Pietrangeli, Carolynn E ^b   Gordon, Robert D ^b   Legendre, Christophe ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CTI Clinical Trial and Consulting Services   (United States)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ABATACEPT; BELATACEPT; BIMOSIAMOSE; BORTEZOMIB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EVEROLIMUS; GLYCYRRHIZIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFOMOSTAT; RAPAMYCIN; REPERTAXIN; RITUXIMAB; SOTRASTAURIN; TACROLIMUS; TASOCITINIB; TP 10; UNCLASSIFIED DRUG;

ANEMIA; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LEUKOPENIA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 77955626157     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.372     Document Type: Erratum

References (49)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
2. Pearson T, Mulgaonkar S, Patel A et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare-the-Nephron (STN) trial. Am J Transplant 2008; 8(Suppl 2): A129.
3. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
4. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
5. Prografs (tacrolimus) Prescribing Information. Astellas Pharma Inc: Deerfield, IL, 2009.
6. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
7. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287.
8. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560-570.
9. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
10. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
11. Rapamunes (sirolimus) Prescribing Information. Wyeth Pharmaceuticals Inc: Philadelphia, PA, 2007.
12. Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87(8 Suppl): S1-S6.
13. Oberbauer R. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus. Transplantation 2009; 87(8 Suppl): S7-S10.
14. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147: 645-657.
15. Kasiske BL, Chakkera HA, Louis TA et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
16. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845-850.
17. Matas AJ, Kandaswamy R, Humar A et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.
18. Ann Surg 2004; 240: 510-516; discussion 516-517.
19. Matas AJ, Gillingham K, Kandaswamy R et al. Kidney transplant half-life (t[1/2]) after rapid discontinuation of prednisone. Transplantation 2009; 87: 100-102.
20. Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
21. Pascual J, Zamora J, Galeano C et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009; 1: CD005632.
22. Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
23. Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885.
24. Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006; 1: 1080-1089.
25. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
26. Orencias (abatacept) Prescribing Information. Bristol-Myers Squibb: Princeton, NJ, 2009.
27. van Gurp E, Weimar W, Gaston R et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008; 8: 1711-1718.
28. Velcades (bortezomib) Prescribing Information. Millennium Pharmaceuticals Inc: Cambridge, MA, 2005.
29. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
30. Everly JJ, Walsh RC, Alloway RR et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
31. Li S, Wang H, Peng B et al. Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci USA 2009; 106: 4349-4354.
32. Hitt E. Efalizumab withdrawn from US market. Medscape Today 2009 (http://www.medscape.com/viewarticle/590862).
33. Vincenti F, Mendez R, Pescovitz M et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7: 1770-1777.
34. Rituxans (rituximab) Prescribing Information. Genentech Inc: San Francisco, CA, 2010.
35. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8-10.
36. Vincenti F, Charpentier B, Vanrenterghem Y et al. A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study). Am J Transplant 2010; 10: 535-546.
37. Durrbach A, Pestana JM, Pearson T et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
38. Nosaka T, van Deursen JM, Tripp RA et al. Defective lymphoid development in mice lacking Jak3. Science 1995; 270: 800-802.
39. Park SY, Saijo K, Takahashi T et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995; 3: 771-782.
40. Mella P, Schumacher RF, Cranston T et al. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain. Hum Mutat 2001; 18: 355-356.
41. Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875-878.
42. Rousvoal G, Si MS, Lau M et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 2006; 19: 1014-1021.
43. Busque S, Leventhal J, Brennan DC et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936-1945.
44. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
45. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
46. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
47. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.
48. Belatacept Injection Cardiovascular and Renal Drug Advisory Committee (CRDAC) Meeting. FDA. March, 2010.
49. Pesu M, Laurence A, Kishore N et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223: 132-142.